Chemical drop at a laboratoy falling inside the test tubes

Featured image by LL28/Getty Images

IPO

Tempus AI prices IPO at 38% cut from valuation peak

The IPO pricing is a reality check that shows even an AI-heavy roadshow pitch must still overcome an unforgiving exit environment for unprofitable VC-backed companies.

AI-powered precision medicine company Tempus AI priced its IPO on Thursday at $37 per share to raise nearly $411 million at a fully diluted market capitalization of $6.38 billion—a 38% discount from its $10.25 billion valuation set in 2022, according to PitchBook data.

While a great result for many investors, the pricing is a tough pill to swallow for others like Google, which bought into the healthtech company at a valuation above $8 billion in 2020. The company’s largest institutional shareholder, Baillie Gifford, held shares worth $350 million at the IPO price.

Tempus is a precision medicine and lab testing provider building a proprietary generative AI platform to improve lab testing, clinical diagnostics and therapeutics development.

Investors have hailed the use case of generative AI for drug discovery. Tempus can capitalize on that hype thanks to a core business that allows it to gather the data needed to train AI for healthcare applications.

Tempus was founded in 2015 by serial entrepreneur Eric Lefkofsky, who became a tech celebrity as the co-founder of Groupon. Some of its earliest investors include Revolution, NEA and T. Rowe Price.

The IPO pricing is a reality check on the limits of even a heavily AI-focused roadshow pitch in an unforgiving exit environment for VC-backed companies. Tempus AI reported net losses of $289.8 million in 2022 and $214.1 million in 2023.

SoftBank, as part of its aggressive pursuit of AI bets, bought into Tempus in late April at $57.31 per share, but with the agreement that it would receive additional shares if the IPO sells shares at a discount to that price.

Healthtech investors will be closely watching Tempus’s debut. “It will test investor appetite for AI-focused IPOs in healthcare,” PitchBook healthcare senior analyst Aaron DeGagne said.

“Tempus will be one of first precision medicine companies to go public since probably 2021,” and a successful debut could pave the way for other unprofitable startups to go public.

Related read: Q1 2024 Medtech report

Featured image by LL28/Getty Images

Learn about our editorial standards.